La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España

This publication has 25 references indexed in Scilit:

• Severe Respiratory Syncytial Virus Bronchiolitis in Infancy and Asthma and Allergy at Age 13
  American Journal of Respiratory and Critical Care Medicine, 2005
• Case-Control Study of the Risk Factors Linked to Respiratory Syncytial Virus Infection Requiring Hospitalization in Premature Infants Born at a Gestational Age of 33–35 Weeks in Spain
  The Pediatric Infectious Disease Journal, 2004
• Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection
  Archives of Disease in Childhood, 2004
• Impact of Wheezing After Respiratory Syncytial Virus Infection on Health-Related Quality of Life
  The Pediatric Infectious Disease Journal, 2004
• Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants
  The Journal of Pediatrics, 2003
• The association between respiratory syncytial virus infection and reactive airway disease
  Respiratory Medicine, 2002
• Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection
  Archives of Disease in Childhood, 2001
• Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons
  The Pediatric Infectious Disease Journal, 2001
• Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion
  The Pediatric Infectious Disease Journal, 1999
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children
  New England Journal of Medicine, 1993